Cargando…

A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial

STUDY OBJECTIVE: A safe alternative to erythropoiesis‐stimulating agents to treat anemia is warranted in patients with cancer and anemia; thus the objective of this trial was to compare the efficacy and safety of intravenous (IV) iron isomaltoside with oral iron in patients with cancer and anemia by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Birgegård, Gunnar, Henry, David, Glaspy, John, Chopra, Rakesh, Thomsen, Lars L., Auerbach, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071650/ https://www.ncbi.nlm.nih.gov/pubmed/26927900 http://dx.doi.org/10.1002/phar.1729

Ejemplares similares

A prospective, multi‐center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON‐IDA trial
por: Auerbach, Michael, et al.
Publicado: (2019)

A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia
por: Derman, Richard, et al.
Publicado: (2017)

Safety of intravenous iron isomaltoside for iron deficiency and iron deficiency anemia in pregnancy
por: Wesström, Jan
Publicado: (2020)

Iron isomaltoside is superior to iron sucrose in increasing hemoglobin in gynecological patients with iron deficiency anemia
por: Derman, Richard, et al.
Publicado: (2018)

Intravenous iron isomaltoside versus oral iron supplementation for treatment of iron deficiency in pregnancy: protocol for a randomised, comparative, open-label trial
por: Markova, Veronika, et al.
Publicado: (2020)

Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON‐IDA/NEPHRO trials
por: Wolf, Myles, et al.
Publicado: (2020)

A Randomized, Open-Label, Non-Inferiority Study of Intravenous Iron Isomaltoside 1,000 (Monofer) Compared With Oral Iron for Treatment of Anemia in IBD (PROCEED)
por: Reinisch, Walter, et al.
Publicado: (2013)

Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia
por: Kalra, Philip A, et al.
Publicado: (2016)

Intravenous Iron Isomaltoside 1000 Reduces Postoperative Anemia in Patients Undergoing Elective Urologic Surgery and Those with Urosepsis
por: Goh, Hyeok Jun, et al.
Publicado: (2020)

Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease
por: Nordfjeld, Kim, et al.
Publicado: (2012)

Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy
por: Hedenus, Michael, et al.
Publicado: (2014)

A 6 month extension trial evaluating safety and efficacy of ferric derisomaltose in patients with iron deficiency anemia: The FERWON‐EXT trial
por: Achebe, Maureen M., et al.
Publicado: (2020)

A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease
por: Reinisch, Walter, et al.
Publicado: (2015)

A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000
por: Pollock, Richard F, et al.
Publicado: (2017)

A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia
por: Kalra, Philip A., et al.
Publicado: (2016)

High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23
por: Dahlerup, Jens Frederik, et al.
Publicado: (2016)

Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta‐analysis
por: Schaefer, Benedikt, et al.
Publicado: (2020)

A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients
por: Bhandari, Sunil, et al.
Publicado: (2015)

P1495: A PHASE III, RANDOMISED CONTROLLED SAFETY, EFFICACY AND COST EFFECTIVENESS TRIAL OF INTRAVENOUS IRON ISOMALTOSIDE (I3R) AND FERRIC CARBOXY MALTOSE (FERIUMR) IN SUBJECTS WITH IRON DEFICIENCY ANEMIA
por: Harikrishnan, P, et al.
Publicado: (2023)

Perioperative changes in haemoglobin and ferritin concentrations from preoperative intravenous iron isomaltoside for iron deficiency anaemia in patients with colorectal cancer: A pilot randomised controlled trial
por: Fung, Pui Lam Polly, et al.
Publicado: (2022)

Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
por: Pollock, Richard F., et al.
Publicado: (2019)

Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
por: Aksan, Ayşegül, et al.
Publicado: (2019)

Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review
por: Glaspy, John A, et al.
Publicado: (2020)

Intravenous ferric derisomaltose for the treatment of iron deficiency anemia
por: Auerbach, Michael, et al.
Publicado: (2021)

Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial
por: Bhandari, Sunil, et al.
Publicado: (2020)

Health-related quality of life in patients with iron deficiency anemia: impact of treatment with intravenous iron
por: Strauss, William E, et al.
Publicado: (2018)

Intravenous Iron Therapy to Treat Anemia in Oncology: A Mapping Review of Randomized Controlled Trials
por: Lim, Jayne, et al.
Publicado: (2023)

Conversion of haemodialysis patients from iron sucrose to iron isomaltoside: a real-world experience
por: Jesus-Silva, Jorge A., et al.
Publicado: (2020)

Randomized Controlled Trial Comparing Ferrous Sulfate and Iron Sucrose in Iron Deficiency Anemia in Pregnancy
por: Chauhan, Neha, et al.
Publicado: (2023)

Introducing iron isomaltoside 1000 (Monofer®)—development rationale and clinical experience
por: Kalra, Philip A.
Publicado: (2011)

Intravenous iron isomaltoside 1000 administered by high single-dose infusions or standard medical care for the treatment of fatigue in women after postpartum haemorrhage: study protocol for a randomised controlled trial
por: Holm, Charlotte, et al.
Publicado: (2015)

Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo‐controlled study (IRON‐CLAD)
por: Makharadze, Tamta, et al.
Publicado: (2021)

The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency
por: Frigstad, Svein Oskar, et al.
Publicado: (2017)

Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome
por: Glaspy, John A., et al.
Publicado: (2021)

Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial
por: Adkinson, N. Franklin, et al.
Publicado: (2018)

Profound Iron Deficiency Anemia and Irreversible Dilated Cardiomyopathy in a Child
por: Wittekind, Samuel G., et al.
Publicado: (2019)

OR13-3 Effects of Iron Isomaltoside versus Ferric Carboxymaltose on Hormonal Control of Phosphate Homeostasis: The PHOSPHARE-IDA04/05 Randomized Controlled Trials
por: Wolf, Myles, et al.
Publicado: (2019)

Treatment of iron deficiency in patients with chronic kidney disease: A prospective observational study of iron isomaltoside (NIMO Scandinavia)
por: Jensen, Gert, et al.
Publicado: (2019)

A prospective observational study of iron isomaltoside in haemodialysis patients with chronic kidney disease treated for iron deficiency (DINO)
por: Mikhail, Ashraf I., et al.
Publicado: (2019)

Differential Pharmacokinetics of Liver Tropism for Iron Sucrose, Ferric Carboxymaltose, and Iron Isomaltoside: A Clue to Their Safety for Dialysis Patients
por: Rostoker, Guy, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pl8r0amcnfv46r4pujl8vtfdg7